KENOSHA, Wis. — February 5, 2026 — Snap-on Incorporated (NYSE: SNA), a leading global innovator, manufacturer and marketer of tools, equipment, diagnostics, repair information and systems solutions for professional users performing critical tasks, today announced 2025 operating results for the fourth quarter and full year. See "Non-GAAP Measures" below for a definition of, and further explanation about, organic sales. "We're encouraged by our fourth quarter results, delivering overall sales growth and maint ...

ONEMAIN HOLDINGS, INC. REPORTS FOURTH QUARTER 2025 RESULTS New York, NY, February 5, 2026 - OneMain Holdings, Inc. (NYSE: OMF), the leader in offering nonprime consumers responsible access to credit, today reported pretax income of $249 million and net income of $204 million for the fourth quarter of 2025, compared to $164 million and $126 million, respectively, in the prior year quarter. Earnings per diluted share were $1.72 in the fourth quarter of 2025, compared to $1.05 in the prior year quarter. Net in ...

Ioanis Jorgali, Investors 629.213.6139 ioanis.jorgali@alliancebernstein.com Carly Symington, Media 629.213.5568 carly.symington@alliancebernstein.com ALLIANCEBERNSTEIN HOLDING L.P. ANNOUNCES FOURTH QUARTER RESULTS GAAP Diluted Net Income of $0.90 per Unit Adjusted Diluted Net Income of $0.96 per Unit Cash Distribution of $0.96 per Unit Nashville, TN, February 5, 2026 - AllianceBernstein L.P. ("AB") and AllianceBernstein Holding L.P. ("AB Holding") (NYSE: AB) today reported financial and operating results fo ...

Financial Performance - Total revenues for 2025 increased 11% to $274.9 billion compared to $247.1 billion in 2024[6] - Shareholders' net income for 2025 was $6.0 billion, or $22.18 per share, up from $3.4 billion, or $12.12 per share in 2024[4] - Adjusted income from operations for 2025 was $8.0 billion, or $29.84 per share, compared to $7.7 billion, or $27.33 per share in 2024[5] - Total revenues for the year ended December 31, 2025, reached $274,900 million, up from $247,121 million in 2024, marking an increase of 11.3%[39] - Shareholders' net income for Q4 2025 was $1,234 million, a decrease of 13.3% compared to $1,424 million in Q4 2024[40] - Adjusted income from operations for the year ended December 31, 2025, was $8,014 million, compared to $7,741 million in 2024, reflecting a growth of 3.5%[40] - The diluted earnings per share for the year ended December 31, 2025, was $22.18, up from $12.12 in 2024, indicating a significant increase of 83.9%[41] Customer Growth - Total customer relationships increased 3% to 188.4 million as of December 31, 2025, from 182.2 million in 2024[10] - Total pharmacy customers increased 4% to 123.6 million as of December 31, 2025, driven by new sales and expansion[10] - Total medical customers are projected to be approximately 18.1 million[25] Future Projections - 2026 adjusted income from operations is projected to be at least $7.950 billion, or at least $30.25 per share[6] - The Cigna Group projects full year 2026 adjusted revenues to be approximately $280.0 billion[24] - The consolidated adjusted income from operations for 2026 is expected to be at least $7.950 billion, equating to at least $30.25 per share[25] - The adjusted SG&A expense ratio is projected to be around 5.0% for 2026[25] - The adjusted effective tax rate is anticipated to be approximately 19.0%[25] - Cash flow from operations is expected to be around $9.0 billion for 2026[25] - Capital expenditures are projected to be approximately $1.3 billion[25] - Shareholder dividends for 2026 are expected to be around $1.6 billion[25] - Cigna Healthcare's adjusted income from operations is expected to be at least $4.5 billion for 2026[25] - Evernorth's adjusted income from operations is projected to be at least $6.9 billion for 2026[25] Operational Performance - Adjusted revenues for Evernorth Health Services increased 17% in Q4 2025 compared to Q4 2024, with adjusted income from operations increasing 2%[16] - Cigna Healthcare adjusted revenues decreased 16% in Q4 2025 compared to Q4 2024, primarily due to the impact of the HCSC transaction[19] - Pharmacy revenues increased to $58,336 million in Q4 2025 from $49,941 million in Q4 2024, representing a growth of 16.0%[39] - Adjusted revenues for Q4 2025 were $72,495 million, up from $65,683 million in Q4 2024, representing a growth of 12.8%[39] - Evernorth Health Services reported pre-tax adjusted income of $2,188 million in Q4 2025, slightly up from $2,146 million in Q4 2024[39] - Cigna Healthcare's pre-tax adjusted income increased to $734 million in Q4 2025 from $511 million in Q4 2024, a growth of 43.7%[39] Shareholder Information - The Board of Directors declared an increase in the quarterly dividend to $1.56 per share, up from $1.51 per share in 2025[6] - The company's shareholders' equity at December 31, 2025, was $41,713 million, compared to $41,033 million at the end of 2024, an increase of 1.7%[39] - The debt-to-capitalization ratio was 43.0% at December 31, 2025, down from 44.9% at September 30, 2025[8] - The weighted average shares outstanding decreased to 265,699 thousand in Q4 2025 from 277,784 thousand in Q4 2024, a decline of 4.3%[39]

Revenue Performance - Total revenues for the three months ended December 31, 2025 were $283.4 million, a decrease of $6.9 million, or 2.4%, compared to the same period in 2024[98]. - Total revenues for the nine months ended December 31, 2025 were $807.1 million, a decrease of $34.2 million, or 4.1%, compared to $841.2 million for the same period in 2024[117]. - North American OTC Healthcare segment revenues decreased by $3.2 million, or 1.4%, primarily due to declines in Eye & Ear Care, Analgesics, and Women's Health categories[100]. - North American OTC Healthcare segment revenues decreased by $32.0 million, or 4.5%, primarily due to a decline in sales in the Eye & Ear Care category[118]. - International OTC Healthcare segment revenues decreased by $3.6 million, or 7.1%, mainly due to a decline in Eye & Ear Care sales, partially offset by an increase in Women's Health[101]. - International OTC Healthcare segment revenues decreased by $2.1 million, or 1.6%, mainly due to a decrease in sales in the Eye & Ear Care category, partially offset by an increase in Women's Health sales[119]. Profitability Metrics - Gross profit for the three months ended December 31, 2025 decreased by $3.7 million, or 2.3%, compared to the same period in 2024, while gross profit margin remained constant at 55.5%[103]. - Gross profit for the nine months ended December 31, 2025 decreased by $15.2 million, or 3.3%, to $449.3 million, while gross profit margin increased to 55.7% from 55.2%[120]. - Contribution margin for the North American OTC Healthcare segment decreased by $1.9 million, or 1.9%, with a margin of 41.6% in Q3 2025, down from 41.8% in Q3 2024[108]. - Contribution margin for the North American OTC Healthcare segment decreased by $4.2 million, or 1.4%, to $285.8 million, with a margin increase to 42.1% from 40.8%[126]. - Contribution margin for the International OTC Healthcare segment decreased by $3.9 million, or 16.9%, with a margin of 40.4% in Q3 2025, down from 45.2% in Q3 2024[109]. - Contribution margin for the International OTC Healthcare segment decreased by $6.0 million, or 10.7%, to $49.8 million, with a margin decrease to 38.9% from 42.8%[127]. Expenses and Financial Position - General and administrative expenses increased by $5.0 million to $86.2 million for the nine months ended December 31, 2025, compared to $81.2 million for the same period in 2024[128]. - Interest expense, net decreased to $30.9 million for the nine months ended December 31, 2025, from $36.9 million for the same period in 2024, with average indebtedness decreasing to $1.0 billion[130]. - The provision for income taxes increased to $56.4 million for the nine months ended December 31, 2025, compared to $45.8 million for the same period in 2024, with an effective tax rate increase to 29.2% from 21.8%[132]. - Cash and cash equivalents decreased by $35.5 million to $62.4 million as of December 31, 2025, with cash provided by operating activities increasing to $214.8 million[134]. - Net cash provided by operating activities increased to $214.8 million for the nine months ended December 31, 2025, up from $189.7 million for the same period in 2024, reflecting a $25.1 million increase primarily due to working capital timing[135]. - Net cash used in investing activities rose significantly to $133.4 million for the nine months ended December 31, 2025, compared to $14.0 million for the same period in 2024, marking a $119.5 million increase primarily due to acquisitions[136]. - Net cash used in financing activities decreased to $118.0 million for the nine months ended December 31, 2025, down from $170.6 million for the same period in 2024, a reduction of $52.6 million attributed to decreased net debt repayments[137]. - As of December 31, 2025, the company had $1.0 billion in outstanding indebtedness, including $40.0 million on the 2012 ABL Revolver and a borrowing capacity of $146.4 million[138]. - The company must maintain a fixed charge ratio greater than 1.0 to 1.0 for the quarter ended December 31, 2025, and was in compliance with applicable financial covenants[140]. - The company has $400.0 million of 5.125% 2019 senior unsecured notes maturing on January 15, 2028, and $600.0 million of 3.750% 2021 senior unsecured notes maturing on April 1, 2031[141]. Strategic Developments - The acquisition of Pillar5 Pharma, Inc. was completed on December 18, 2025, funded through cash and an asset-based revolving credit facility[89]. - Economic uncertainty continues to impact supply chains, labor availability, and input costs, potentially affecting product demand and operational performance[92]. - The company has observed a shift in consumer purchasing patterns towards online channels, influencing retailer purchasing strategies[92]. - The company reported no material changes to its critical accounting policies during the nine months ended December 31, 2025[142]. - The company anticipates compliance with financial and restrictive covenants during the next twelve months based on normal operations[140]. - The company faces various risks including supply chain disruptions, competition, and dependence on third-party manufacturers[146]. - The company’s exposure to market risk has not changed materially since March 31, 2025[149].

Company Operations - As of December 31, 2025, Regis Corporation operated 3,829 locations, including 3,551 franchised salons and 278 company-owned salons[109]. Financial Performance - System-wide revenue for the three months ended December 31, 2025, was $260.8 million, a decrease of 4.8% from $274.1 million in the same period of 2024[114]. - Total system-wide same-store sales decreased by 0.1% for the three months ended December 31, 2025, compared to a decrease of 1.6% in the same period of 2024[114]. - Company-owned salon revenue increased by $15.7 million, or 448.6%, from $3.5 million to $19.2 million for the three months ended December 31, 2025, due to the Alline acquisition[125]. - Franchise revenue decreased by $5.4 million and $11.8 million during the three and six months ended December 31, 2025, primarily due to a decrease in franchise salon count[141]. - Franchise adjusted EBITDA totaled $6.2 million and $12.6 million for the three and six months ended December 31, 2025, reflecting a decrease of $0.2 million and $1.8 million, respectively[142]. - Company-owned salon revenue increased by $15.7 million and $35.2 million during the three and six months ended December 31, 2025, primarily due to the Alline acquisition[145]. - Company-owned salon adjusted EBITDA improved by $1.1 million and $2.9 million for the three and six months ended December 31, 2025, respectively[146]. Expenses and Liabilities - Royalties decreased by $1.2 million, or 8.1%, during the three months ended December 31, 2025, primarily due to a decrease in franchise salon count[121]. - General and administrative expenses decreased by $0.9 million, or 8.0%, during the three months ended December 31, 2025, primarily due to lower broker fees and severance[126]. - Rent expense increased by $1.5 million, or 71.4%, during the three months ended December 31, 2025, due to expenses associated with salons from the Alline acquisition[127]. - Company-owned salon expenses increased by $11.8 million, or 621.1%, from $1.9 million to $13.7 million for the three months ended December 31, 2025, primarily due to the Alline acquisition[130]. - Depreciation and amortization increased by $0.3 million, or 60.0%, during the three months ended December 31, 2025, due to assets acquired in the Alline acquisition[131]. - Interest expense increased by $0.5 million and $0.8 million for the three and six months ended December 31, 2025, respectively, due to higher debt outstanding compared to the prior year[133]. - The company recognized a $1.0 million gain on earn-out liability related to the Alline acquisition during the six months ended December 31, 2025[134]. Cash Flow and Capitalization - As of December 31, 2025, cash and cash equivalents were $18.4 million, with $17.6 million in the United States and $0.8 million in Canada[151]. - Cash provided by operating activities was $3.9 million for the six months ended December 31, 2025, compared to $0.8 million in the prior year[155]. - The company's debt to capitalization ratio was 40.0% as of December 31, 2025, compared to 40.3% as of June 30, 2025[159]. - The company has $54.6 million remaining under the approved stock repurchase program as of December 31, 2025[160]. Market Risks and Strategic Considerations - The company is exposed to market risks from changes in interest rates and foreign currency exchange rates, with no material changes reported since the last annual report[164]. - Forward-looking statements reflect management's best judgment but are subject to numerous risks and uncertainties that could materially affect actual results[162]. - The company emphasizes the importance of maintaining satisfactory relationships with key partners, such as Walmart, to drive business success[162]. - There is a reliance on franchise royalties and the overall success of franchisees' salons, which are critical for revenue generation[162]. - The company faces challenges in attracting, training, and retaining talented stylists and salon leaders, impacting operational efficiency[162]. - Data security and privacy compliance are highlighted as significant concerns, particularly regarding the protection of sensitive information[162]. - The company is focused on implementing cost reduction initiatives to achieve expected cost savings and maintain competitiveness[162]. - The ability to generate sufficient cash flow to meet debt service obligations is a key financial consideration for the company[162]. - The company is currently undergoing a search for a new CEO, which is crucial for future leadership and strategic direction[162]. - Potential liabilities related to the employee retention credit received by Alline may pose financial risks[162].

For the quarterly period ended: December 27, 2025 OR TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ☐ 1934 Commission File Number: 001-14041 HAEMONETICS CORPORATION (Exact name of registrant as specified in its charter) Massachusetts 04-2882273 (State or other jurisdiction of incorporation or organizat ...

Exhibit 99.1 Prestige Consumer Healthcare Inc. Reports Third Quarter and Year-to-Date Fiscal 2026 Results Reported revenues for the first nine months of fiscal 2026 totaled $807.1 million and compared to revenues of $841.2 million for the first nine months of fiscal 2025. Revenues decreased 4.1% versus the prior year comparable period and 3.9% excluding the impact of foreign currency. The revenue performance for the first nine months reflected the limited ability to supply strong demand for Clear Eyes® as w ...

Investor Contacts Media Contact Olga Guyette, Vice President-Investor Relations & Treasury Josh Gitelson, Sr. Director-Communications (781) 356-9763 (781) 356-9776 olga.guyette@haemonetics.com josh.gitelson@haemonetics.com David Trenk, Manager-Investor Relations (203) 733-4987 david.trenk@haemonetics.com Haemonetics Reports Third Quarter and Year-to-Date Fiscal 2026 Results; Raises Total Company Fiscal 2026 Guidance Boston, MA, February 5, 2026 - Haemonetics Corporation (NYSE: HAE) reported financial result ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ___________________________________________ FORM 10-K ___________________________________________ (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number: 001-37580 ____________________________________ ...